Law
Offices of Howard G. Smith announces that a class action lawsuit has
been filed in the United States District Court for the Middle District
of Tennessee on behalf of all purchasers of the securities of Provectus
Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (NYSE:PVCT)
between December 17, 2013 and May 22, 2014, inclusive (the “Class
Period”).
Provectus is a development-stage biopharmaceutical company engaged in
developing pharmaceuticals for oncology and dermatology indications. The
Company’s product line includes PV-10, which has completed a Phase II
study for metastatic melanoma and a Phase I study for breast cancer, and
is in various stages of clinical development for certain other cancer
indications. The Complaint alleges that defendants misrepresented and/or
failed to disclose material adverse facts concerning the status of PV-10
and preparations for a Phase III study of the drug.
On May 23, 2014, the Company announced that its application for a
designation of PV-10 as “Breakthrough Therapy” was denied by the Food
and Drug Administration. According to the Company, the FDA denied the
designation because the agency’s review indicated that “the data upon
which the Company based its request for designation of PV-10 as a
Breakthrough Therapy for the treatment of patients with locally advanced
cutaneous melanoma was insufficient to demonstrate substantial
improvement over existing therapies.”
If you are a member of the Class described above, you have until July
28, 2014, to move the Court to serve as lead plaintiff, if you meet
certain legal requirements. To be a member of the Class you need not
take any action at this time; you may retain counsel of your choice or
take no action and remain an absent member of the Class. If you wish to
learn more about this action, please contact Howard G. Smith, Esquire,
of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free
at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at http://www.howardsmithlaw.com.
Copyright Business Wire 2014